Vermillion And The OVA1 Experience
You may also be interested in...
Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery
Laboratory Corporation of America pulled its early-stage ovarian cancer test service from the market last week in response to FDA scrutiny, but the lab giant called the agency's actions leading up to the withdrawal "unprecedented.
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.